Literature DB >> 12051708

The nuclear function of angiogenin in endothelial cells is related to rRNA production.

Zheng-ping Xu1, Takanori Tsuji, James F Riordan, Guo-fu Hu.   

Abstract

Angiogenin is a potent angiogenic protein whose inhibition is known to prevent human tumor growth in athymic mice. It is secreted by both tumor and normal cells; and interacts with endothelial and smooth muscle cells to induce a wide range of cellular responses including cell migration and invasion, proliferation, and formation of tubular structures. Angiogenin is rapidly endocytosed and translocated to the cell nucleus where it accumulates in the nucleolus and binds to DNA. Although nuclear translocation is necessary for its angiogenic activity, the nuclear function of angiogenin is unclear. Here we report that exogenous angiogenin enhances the production of 45S rRNA in endothelial cells, and reduction of endogenous angiogenin inhibits its transcription. In a nuclear run-on assay, angiogenin stimulates RNA synthesis including that containing the initiation site sequences of 45S rRNA. This suggests that the nuclear function of angiogenin relates to its capacity to induce rRNA synthesis. Because rRNA transcription is essential for the synthesis of new ribosomes that are necessary for protein translation and cell growth, inhibition of angiogenin-stimulated transcription of rRNA may inhibit angiogenesis and therefore, would serve as a molecular target for therapeutic intervention. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051708     DOI: 10.1016/S0006-291X(02)00479-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  52 in total

Review 1.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

Review 2.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

3.  Angiogenin stimulates ribosomal RNA transcription by epigenetic activation of the ribosomal DNA promoter.

Authors:  Jinghao Sheng; Wenhao Yu; Xiangwei Gao; Zhengping Xu; Guo-Fu Hu
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

4.  Can't you hear me knocking: contact-dependent competition and cooperation in bacteria.

Authors:  Allison M Jones; David A Low; Christopher S Hayes
Journal:  Emerg Top Life Sci       Date:  2017-04-21

5.  Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Authors:  Sujoy Dutta; Chirosree Bandyopadhyay; Virginie Bottero; Mohanan V Veettil; Lydia Wilson; Michael R Pins; Karen E Johnson; Case Warshall; Bala Chandran
Journal:  Mol Oncol       Date:  2014-01-04       Impact factor: 6.603

Review 6.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

7.  Angiogenin as a molecular target for the treatment of prostate cancer.

Authors:  Shuping Li; Soichiro Ibaragi; Guo-Fu Hu
Journal:  Curr Cancer Ther Rev       Date:  2011-05

Review 8.  New insights into the role of angiogenin in actin polymerization.

Authors:  Mikhail G Pyatibratov; Alla S Kostyukova
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

9.  Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation.

Authors:  Koji Kishimoto; Shoko Yoshida; Soichiro Ibaragi; Norie Yoshioka; Guo-Fu Hu; Akira Sasaki
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

10.  A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells.

Authors:  Trish T Hoang; I Caglar Tanrikulu; Quinn A Vatland; Trieu M Hoang; Ronald T Raines
Journal:  Mol Cancer Ther       Date:  2018-10-03       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.